CD40-Activated B Cell Cancer Vaccine Improves Remission and Survival in Dogs with Lymphoma
Author Information
Author(s): Sorenmo Karin U., Krick Erika, Coughlin Christina M., Overley Beth, Gregor Thomas P., Vonderheide Robert H., Mason Nicola J.
Primary Institution: University of Pennsylvania
Hypothesis
Can CD40-activated B cell vaccines improve clinical outcomes in dogs with non-Hodgkin's lymphoma?
Conclusion
The CD40-B cell vaccine is safe and can improve the rate of durable remissions and lymphoma-specific survival in dogs with non-Hodgkin's lymphoma.
Supporting Evidence
- 79% of vaccinated dogs eventually relapsed, but 21% achieved durable remissions.
- Vaccination did not increase mortality compared to the control group.
- 40% of relapsed vaccinated dogs achieved durable second remissions with salvage therapy.
Takeaway
This study tested a new vaccine for dogs with lymphoma, and it helped some dogs stay healthy longer after treatment.
Methodology
A clinical trial was conducted with dogs diagnosed with non-Hodgkin's lymphoma, comparing vaccinated dogs to a control group receiving standard chemotherapy.
Potential Biases
Potential selection bias in the control group as they were not randomized.
Limitations
The sample size was small, and the study was not randomized.
Participant Demographics
Privately owned dogs with non-Hodgkin's lymphoma, average age around 8 years.
Statistical Information
P-Value
p=0.025
Confidence Interval
95% CI, 158–314 days
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website